Clinical trials: Advanced Solid Malignancy
Advanced Solid Tumors
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.
- Trial name
- NCT00793975
- Testing
- IMC-1121B, 1121B
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to other places in the body (advanced).
- Trial name
- NCT03907475
- Testing
- Biopsy Procedure, Biospecimen Collection, Capecitabine
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult subjects with advanced refractory solid tumor malignancies, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose…
- Trial name
- NCT03790488
- Testing
- JTX-4014
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Jounce Therapeutics, Inc.
Advanced Solid Tumor
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability when given as a single medication and as a combined medication in adults with solid tumors, where the…
- Trial name
- NCT07128303
- Testing
- GS-5319, Carboplatin, Pemetrexed
- Where
- 12 sites in United States, South Korea and 1 more
- Volunteers
- 476 people
- Sponsor
- Gilead Sciences
Non-small Cell Lung Cancer, Glioblastoma Multiforme
Evaluation of GLR2007 for Advanced Solid Tumors
Evaluation of GLR2007 for Advanced Solid Tumors
- Trial name
- NCT04444427
- Testing
- GLR2007
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Advanced Solid Tumors Cancer
ORB-021 In Patients With Advanced Solid Tumors
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor.
- Trial name
- OR2-01 (NCT06607939)
- Testing
- ORB-021
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Orionis Biosciences Inc
Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm
Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors
This clinical trial studies whether educational tools work to improve early advance care planning (ACP) in adolescents and young adults (AYAs) with solid tumors that may have spread from where they first started to nearby tissue…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm, Recurrent Advanced Malignant Solid Neoplasm
- Trial name
- NCT07174661
- Testing
- Advance Care Planning, Educational Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Cancer, Solid Cancer
Immune Modulation With PRaG-1 Treatment
The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment.
- Trial name
- NCT07002502
- Testing
- PRaG-1(cordycepin tablet)
- Volunteers
- 19 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Locally Advanced Solid Tumours, Metastatic Solid Tumours
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
This Phase Ib study will identify the Maximum Tolerated Dose (MTD) of AZD1775 monotherapy when administered orally once daily (QD) or two times per day (BID) on Days 1 to 5 followed by 9 days of rest in 14-day cycles, or QD on a…
- Conditions
- Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
- Trial name
- NCT02610075
- Testing
- AZD1775
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Metastatic Neoplasm
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose…
- Trial name
- NCT07030712
- Testing
- MK-8294, CD8 PET Tracer
- Where
- 8 sites in United States, Israel and 1 more
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor in Advanced Stage
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Evaluation of pharmacokinetic profile of SPARC1028
- Trial name
- NCT01305512
- Testing
- SPARC1028
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Advanced or Metastatic Solid Tumors
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in participants with advanced or metastatic solid…
- Trial name
- MarkV-01 (NCT05957081)
- Testing
- PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab(KEYTRUDA®), PMC-309 Dose Expansion
- Where
- 4 sites in Australia
- Volunteers
- 67 people
- Sponsor
- PharmAbcine
Advanced Solid Tumor, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors.
- Conditions
- Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety
- Trial name
- SCARCE (NCT05915481)
- Testing
- Cadonilimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Breast Cancer, Ovarian Epithelial Cancer Recurrent
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
This is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors, and determine preliminary efficacy of the…
- Conditions
- Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02014337
- Testing
- Mifepristone and Eribulin in combination
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- Corcept Therapeutics
Solid Tumor
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or…
- Trial name
- NCT04235101
- Testing
- SYD985 + Niraparib
- Where
- 6 sites in Belgium, Netherlands and 1 more
- Volunteers
- 32 people
- Sponsor
- Byondis B.V.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called mTOR mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06385496
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05774873
- Testing
- IBI334
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neoplasms
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with…
- Trial name
- NCT07276373
- Testing
- Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Solid Tumor, Cancer
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally…
- Conditions
- Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02705105
- Testing
- Mogamulizumab + Nivolumab
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Kyowa Kirin, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.